<SEC-DOCUMENT>0001682852-22-000020.txt : 20220504
<SEC-HEADER>0001682852-22-000020.hdr.sgml : 20220504
<ACCEPTANCE-DATETIME>20220504065823
ACCESSION NUMBER:		0001682852-22-000020
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220504
DATE AS OF CHANGE:		20220504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moderna, Inc.
		CENTRAL INDEX KEY:			0001682852
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				813467528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38753
		FILM NUMBER:		22889759

	BUSINESS ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6177146500

	MAIL ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Moderna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160822
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mrna-20220504.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:57c80b23-146b-4666-8a25-01ef75ff6d5d,g:c81cb976-5c8b-46ea-bc1a-80182ef42bf5,d:13423186f74743c3b0bc0092e6f35888--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrna-20220504</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF80L2ZyYWc6ZmY1OTUxOTFmMzgxNGQ4YjljMmZkZmNkYzMyY2U1MzUvdGFibGU6MTA3OTFjNjk4OTdiNGI5ZGI0MjYyNWI3ZTg1NzRjMWIvdGFibGVyYW5nZToxMDc5MWM2OTg5N2I0YjlkYjQyNjI1YjdlODU3NGMxYl8xLTEtMS0xLTEyMjg1Mw_c46e6ba8-77be-44f1-bb6b-1fc4995043c8">0001682852</ix:nonNumeric><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF80L2ZyYWc6ZmY1OTUxOTFmMzgxNGQ4YjljMmZkZmNkYzMyY2U1MzUvdGFibGU6MTA3OTFjNjk4OTdiNGI5ZGI0MjYyNWI3ZTg1NzRjMWIvdGFibGVyYW5nZToxMDc5MWM2OTg5N2I0YjlkYjQyNjI1YjdlODU3NGMxYl8yLTEtMS0xLTEyMjg1Mw_83499b90-f321-4570-a2c8-7e9a6fabc881">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrna-20220504.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-04</xbrli:startDate><xbrli:endDate>2022-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i13423186f74743c3b0bc0092e6f35888_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.416%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM&#160;<ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NzIyOWVkMmQ3NTNmNDY3MmI4MDc1ZDkzYTdkZDE1YTUvdGFibGVyYW5nZTo3MjI5ZWQyZDc1M2Y0NjcyYjgwNzVkOTNhN2RkMTVhNV8wLTAtMS0xLTEyMjg1My90ZXh0cmVnaW9uOjlkMjYwNTAzMjk2NTRiN2ZiNzdhNzE5ZDYyYTQ1YzQyXzk_1077efb2-e8d7-4958-9064-b60876f1a62d">8-K</ix:nonNumeric></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18yMjU_65f4f0b5-7caa-4499-846a-9c3e37d9fe01">May&#160;4, 2022</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.416%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18xMjI5_467ecf59-545f-4300-828e-dfa8894ead5e">MODERNA, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.416%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.750%"><tr><td style="width:1.0%"></td><td style="width:33.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NTEyODg1YTk0Y2E1NDNhZjkyZTIxYmE5MGEyZjFjODQvdGFibGVyYW5nZTo1MTI4ODVhOTRjYTU0M2FmOTJlMjFiYTkwYTJmMWM4NF8wLTAtMS0xLTEyMjg1Mw_11008b18-cc38-411b-8a08-cfb8fc5adff7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NTEyODg1YTk0Y2E1NDNhZjkyZTIxYmE5MGEyZjFjODQvdGFibGVyYW5nZTo1MTI4ODVhOTRjYTU0M2FmOTJlMjFiYTkwYTJmMWM4NF8wLTItMS0xLTEyMjg1Mw_0dbe28cd-b1bb-4840-8875-76df0b8418b8">001-38753</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NTEyODg1YTk0Y2E1NDNhZjkyZTIxYmE5MGEyZjFjODQvdGFibGVyYW5nZTo1MTI4ODVhOTRjYTU0M2FmOTJlMjFiYTkwYTJmMWM4NF8wLTQtMS0xLTEyMjg1Mw_990b5255-ceee-4cb1-ad4a-7fafe0ddccdb">81-3467528</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(IRS Employer Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.055%"><tr><td style="width:1.0%"></td><td style="width:49.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OWIwM2I3Y2MwYTcxNGU3OWJjNTU3MTdjZDU5OTA4ZGQvdGFibGVyYW5nZTo5YjAzYjdjYzBhNzE0ZTc5YmM1NTcxN2NkNTk5MDhkZF8wLTAtMS0xLTEyMjg1Mw_fb5cd75b-59fb-411a-a547-dcb6994fc4d6">200 Technology Square</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OWIwM2I3Y2MwYTcxNGU3OWJjNTU3MTdjZDU5OTA4ZGQvdGFibGVyYW5nZTo5YjAzYjdjYzBhNzE0ZTc5YmM1NTcxN2NkNTk5MDhkZF8xLTAtMS0xLTEyMjg1My90ZXh0cmVnaW9uOjgzOWY3MTAzNGI2NDQ0ZWJiYjkxZmM1NjNlMTk1Y2JiXzQ_21f2cd22-5290-4537-aa85-cf3eba9c9a40">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OWIwM2I3Y2MwYTcxNGU3OWJjNTU3MTdjZDU5OTA4ZGQvdGFibGVyYW5nZTo5YjAzYjdjYzBhNzE0ZTc5YmM1NTcxN2NkNTk5MDhkZF8xLTAtMS0xLTEyMjg1My90ZXh0cmVnaW9uOjgzOWY3MTAzNGI2NDQ0ZWJiYjkxZmM1NjNlMTk1Y2JiXzg_9faa7cfe-ae46-49dd-82b8-3b83b4b371d0">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OWIwM2I3Y2MwYTcxNGU3OWJjNTU3MTdjZDU5OTA4ZGQvdGFibGVyYW5nZTo5YjAzYjdjYzBhNzE0ZTc5YmM1NTcxN2NkNTk5MDhkZF8xLTItMS0xLTEyMjg1Mw_ab8fbe07-b014-4e54-ac94-529ec9f66d77">02139</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip code)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18xMjMx_48e1d516-acd3-4349-8663-977f1d4e5f36">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18xMjMy_7aa10523-56e5-4471-a585-420aeff0aa2b">714-6500</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.416%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K&#160;filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.055%"><tr><td style="width:1.0%"></td><td style="width:5.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6ODcxODQwZjIwYTkyNGZiNjhhMTdjZjRlNDI5MjgyMmIvdGFibGVyYW5nZTo4NzE4NDBmMjBhOTI0ZmI2OGExN2NmNGU0MjkyODIyYl8wLTAtMS0xLTEyMjg1Mw_3e0d64bb-0afb-488e-840b-983bff624edd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.055%"><tr><td style="width:1.0%"></td><td style="width:5.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OGIzMGFlMjRmMDBmNGJmZmFjMWNkZTg2NzUxM2E5MzgvdGFibGVyYW5nZTo4YjMwYWUyNGYwMGY0YmZmYWMxY2RlODY3NTEzYTkzOF8wLTAtMS0xLTEyMjg1Mw_4609ea94-b4f4-4115-b9f6-dbfa5db5b089">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.055%"><tr><td style="width:1.0%"></td><td style="width:5.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6MTU3NjkwZThiNGEzNDg1YzhmYzZhN2UwNWI4NjlkMDAvdGFibGVyYW5nZToxNTc2OTBlOGI0YTM0ODVjOGZjNmE3ZTA1Yjg2OWQwMF8wLTAtMS0xLTEyMjg1Mw_eb75bb3a-510b-462e-8cc7-40d5003dbf04">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17CFR&#160;240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.055%"><tr><td style="width:1.0%"></td><td style="width:5.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6ZTY1MGM1ZTY3ZjkyNDhlOTk0YmUzMDkwMjI0YjIxZDMvdGFibGVyYW5nZTplNjUwYzVlNjdmOTI0OGU5OTRiZTMwOTAyMjRiMjFkM18wLTAtMS0xLTEyMjg1Mw_915bdefb-0564-42a4-b76b-22680d7161ce">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR&#160;240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:31.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NDQxYThlOTU4YjcyNDljMzgxM2MwY2FhOGI2ZjJhZWYvdGFibGVyYW5nZTo0NDFhOGU5NThiNzI0OWMzODEzYzBjYWE4YjZmMmFlZl8xLTAtMS0xLTEyMjg1Mw_323b09ad-e769-47d0-aaa4-525a29265875">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NDQxYThlOTU4YjcyNDljMzgxM2MwY2FhOGI2ZjJhZWYvdGFibGVyYW5nZTo0NDFhOGU5NThiNzI0OWMzODEzYzBjYWE4YjZmMmFlZl8xLTItMS0xLTEyMjg1Mw_c4086018-3488-4cf8-8a95-537ac08bb645">MRNA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NDQxYThlOTU4YjcyNDljMzgxM2MwY2FhOGI2ZjJhZWYvdGFibGVyYW5nZTo0NDFhOGU5NThiNzI0OWMzODEzYzBjYWE4YjZmMmFlZl8xLTQtMS0xLTEyMjg1Mw_fe3d0b5e-2505-4dc5-b7f9-fe66965b0cdd">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160; &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18xMjMz_d463228a-3fee-4d0c-9701-e346968ec747">&#9744;</ix:nonNumeric></span></div><div style="text-align:right"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160; &#160;&#160;&#160;&#160;&#9744;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i13423186f74743c3b0bc0092e6f35888_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On <ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xMC9mcmFnOmM4NjdjYzljY2JlYTRjZjViMWNiODg0ZDBiYjllZjMzL3RleHRyZWdpb246Yzg2N2NjOWNjYmVhNGNmNWIxY2I4ODRkMGJiOWVmMzNfNjY_65f4f0b5-7caa-4499-846a-9c3e37d9fe01">May&#160;4, 2022</ix:nonNumeric>, Moderna, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"></td><td style="width:6.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit9912022q1pressrelea.htm">Press release issued by Moderna, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit9912022q1pressrelea.htm">May 4, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:51.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MODERNA, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: <ix:nonNumeric contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xMC9mcmFnOmM4NjdjYzljY2JlYTRjZjViMWNiODg0ZDBiYjllZjMzL3RhYmxlOjljMjBmNmRhNTdiOTRiOThiNjg2YTA2ZTc5OGZlNGViL3RhYmxlcmFuZ2U6OWMyMGY2ZGE1N2I5NGI5OGI2ODZhMDZlNzk4ZmU0ZWJfMi0wLTEtMS0xMjI4NTMvdGV4dHJlZ2lvbjo2YmYyMjNmZDY2OTg0YzMyYjQwYzVkZDc2MWY5OWFiN18xMA_65f4f0b5-7caa-4499-846a-9c3e37d9fe01">May&#160;4, 2022</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David W. Meline</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit9912022q1pressrelea.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie4ff1c7a0da344909bd16d96b290b608_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates</font></div><div style="margin-bottom:6pt;padding-left:11.25pt;padding-right:11.25pt;text-align:center"><font><br></font></div><div id="ie4ff1c7a0da344909bd16d96b290b608_314"></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">First quarter 2022 revenues of $</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">6.1 billion</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#59; GAAP net-income of $</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">3.7 billion</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#160;and GAAP diluted EPS of $</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">8.58</font></div><div><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Moderna reiterates its 2022 signed advance purchase agreements of approximately $21 billion</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company expects to have four programs in Phase 3 in the second quarter&#58; Omicron-containing bivalent COVID booster, flu, RSV, CMV</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CAMBRIDGE, Mass.&#8212;(ACCESS WIRE)&#8212;May 4, 2022&#8212;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Moderna, Inc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. (Nasdaq&#58; MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the first quarter of fiscal year 2022.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The Moderna team delivered a strong Q1 performance and I am thankful for the progress our team continues to make as we advance our pipeline of mRNA medicines. Today, we are reiterating our signed advanced purchase agreements for 2022 of $21 billion. In the second quarter, we expect to have four programs in late-stage Phase 3 studies including our Omicron-containing bivalent COVID booster, seasonal flu, RSV and CMV vaccine candidates.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Beginning in the fall of 2022, our robust Phase 3 pipeline could lead to three respiratory commercial launches over the next two to three years.&#160;We also look forward to advancing our therapeutic programs and sharing proof-of-concept readouts on our rare genetic disease programs for propionic acidemia and methylmalonic acidemia, and on our personalized cancer vaccine program this year,&#8221; said St&#233;phane Bancel, Chief Executive Officer of Moderna. &#8220;I would like to thank the global Moderna team for their commitment to our mission. mRNA has changed the future of medicine and I look forward to continuing our impact on human health. This is just the beginning.&#8221;</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent progress includes&#58;</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Respiratory Vaccines</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submitted a EUA request to U.S. FDA for a 25 &#956;g two-dose primary series of mRNA-1273 in</font><font style="background-color:#f8fdff;color:#053f68;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">children 6 months to under 6 years of age&#59; similar requests underway with international regulatory authorities</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Positive initial data on booster dose of bivalent candidate based on the wild-type and Beta variant (mRNA-1273.211)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Positive Phase 2 interim analysis of seasonal flu vaccine candidate (mRNA-1010)&#59; Phase 3 study in the Southern Hemisphere expected to begin in the second quarter</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Moderna continues to progress respiratory vaccine pipeline with positive Phase 1 data on next-generation, refrigerator-stable COVID vaccine candidate (mRNA-1283), a new combination respiratory vaccine candidate (mRNA-1230) against SARS-CoV-2 virus, influenza virus and RSV and a new vaccine candidate (mRNA-1287) against the four endemic human coronaviruses (HCoV-229E, -NL63, -OC43 and -HKU1)</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Latent Vaccines</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">First participants dosed in Phase 1 study of HIV vaccine candidate with germline targeting approach (mRNA-1644) </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">First participants dosed in Phase 1 study of HIV trimer mRNA vaccine candidate (mRNA-1574)</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Public Health Vaccines</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The U.S. FDA completed its review of the investigational new drug (IND) application of Moderna&#8217;s Nipah virus vaccine candidate (mRNA-1215), allowing it to proceed to clinic</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Therapeutics</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The first cohort of the&#160;Phase 1&#47;2&#160;Paramount&#160;study&#160;of propionic acidemia candidate (mRNA-3927) is fully enrolled. Moderna is enrolling patients into additional cohorts. All five patients eligible for the Open&#160;Label Extension (OLE) study have elected to participate.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The first cohort of the&#160;Phase 1&#47;2 Landmark study&#160;of methylmalonic acidemia candidate (mRNA-3705) is fully enrolled. Moderna is enrolling patients into additional cohorts. The one patient eligible to participate in the OLE study has elected to participate.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moderna</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;now has 46 programs in development across 43 development candidates</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, of which 29 are currently in active clinical trials. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s updated pipeline can be found at </font><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.modernatx.com&#47;pipeline</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;Moderna&#160;and collaborators have published more than 115 peer reviewed manuscripts.</font></div><div id="ie4ff1c7a0da344909bd16d96b290b608_4"></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Quarter 2022 Financial Results</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Revenue&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Total revenue was $6.1 billion for the first quarter of 2022, compared to $1.9 billion for the same period in 2021. The increase in 2022 was primarily due to increased product sales. Product sales for the first quarter of 2022 were $5.9 billion from sales of the Company's COVID vaccine, compared to $1.7 billion in the first quarter of 2021. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cost of Sales&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Cost of sales was $1.0 billion, or 17%, of product sales for the first quarter of 2022, including third-party royalties of $207 million. Cost of sales was $193 million, or 11%, of product sales, for the first quarter of 2021. The increase in cost of sales as a percentage of product sales in 2022 was mainly driven by the lack of the pre-launch inventory benefit (that impacted the first quarter of 2021), coupled with inventory write-downs and a current period expense related to firm purchase commitments. The increase was partially offset by a favorable customer mix, and benefits from the scale up of our manufacturing processes. If inventory sold for the three months ended March 31, 2021 was valued at cost, Moderna&#8217;s cost of sales for the period would have been $377 million, or 22%, of the Company&#8217;s product sales.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Research and Development Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Research and development expenses were $554 million for the first quarter of 2022, compared to $401 million for the same period in 2021. The increase in spending in 2022 was mainly due to increases in personnel-related costs, clinical trial expenses, technology and facility-related costs, and consulting and outside services.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Selling, General and Administrative Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Selling, general and administrative expenses were $268&#160;million for the first quarter of 2022, compared to $77&#160;million for the same period in 2021. The growth in spending in 2022 was mainly due to an endowment to the Moderna Charitable Foundation and increases in distributor fees, personnel-related costs, and consulting and outside services.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Provision for Income Taxes&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The effective tax rate was 14% for the first quarter of 2022, compared to 3% for the same period in 2021. Income taxes were $572 million for the first quarter of 2022, compared to $39 million for the same period in 2021. The increase in income tax provision was primarily due to an increase in pre-tax income and a higher effective tax rate in 2022, as 2021 included tax benefits related to the release of the valuation allowance on the majority of our deferred tax assets.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Net Income&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net income was $3.7 billion for the first quarter of 2022, compared to $1.2 billion for the same period in 2021. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Earnings Per Share&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Diluted EPS was $8.58 for the first quarter of 2022, compared to $2.84 for the same period in 2021.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="background-color:#ffffff;color:#000000;font-family:'Lato',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Includes separate COVID Vaccine (mRNA-1273) programs in development for adults, pediatrics &#38; adolescents and separate RSV vaccine (mRNA-1345) programs in development for adults and pediatrics</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash Position&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash, cash equivalents and investments as of March 31, 2022 and December 31, 2021 were $19.3 billion and $17.6 billion, respectively.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Net Cash Provided By Operating Activities&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $2.8 billion for the three months ended March 31, 2022, compared to $3.0 billion for the same period in 2021. Net cash provided by operating activities decreased in 2022, primarily attributable to revenue recognized from deferred revenue in excess of customer deposits received, partially offset by increased product sales and higher collection of receivables. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash Used for Purchases of Property and Equipment&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Cash used for purchases of property and equipment was $132 million for the three months ended March 31, 2022, compared to $35 million for the same period in 2021. The increase was primarily driven by the Company&#8217;s business expansion.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash Used for Repurchase of Common Stock&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Cash used for repurchases of common stock was $623 million for the three months ended March 31, 2022. Moderna did not conduct share repurchases prior to the fourth quarter of 2021. From the end of the third quarter of 2021 to the end of the first quarter of 2022, the Company repurchased 7 million shares, reducing the number of common shares outstanding from 405 million to 400 million, more than offsetting 2 million shares of common stock issued in connection with equity compensation over this period.</font></div><div id="ie4ff1c7a0da344909bd16d96b290b608_399"></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022 Financial Framework</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advanced Purchase Agreements (APAs)&#58;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moderna&#8217;s 2022 APAs for product sales are approximately $21 billion. Moderna believes that COVID market dynamics will result in sales slightly larger in the second half of 2022 than in the first half.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cost of Sales&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cost of sales as percentage of product sales are&#160;expected to be&#160;in the low-to-mid 20s&#160;percentage&#160;range.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Research &#38; Development (R&#38;D) and Selling, General &#38; Administrative (SG&#38;A) Expenses</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Full year expenses expected to be approximately $4 billion.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Tax Rate&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company expects an effective tax rate for the full year in the mid-teen percentage range.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Capital Expenditures&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expect capital investments for 2022 in the range of $0.6-$0.8 billion.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Share Repurchase Program&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As announced last quarter, the Board of Directors authorized a share repurchase program for $3 billion in February 2022 to return excess capital to shareholders. The previous program of $1 billion announced in August 2021 has been fully utilized as of the end of January 2022. </font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Management Updates</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Jorge Gomez will join Moderna as Chief Financial Officer effective May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, St&#233;phane Bancel. Mr. Gomez joins Moderna from Dentsply Sirona, Inc. (Nasdaq&#58; XRAY) where he served as Executive Vice President &#38; Chief Financial Officer since August 2019. At Dentsply Sirona, he was responsible for leading the global finance organization, including strategic finance, FP&#38;A, Accounting, Treasury, Tax, Corporate Audit and Investor Relations, and the Information Technology function. In addition, Mr. Gomez was responsible for leading Dentsply Sirona's sustainability and ESG program. David Meline, Moderna's current CFO, has decided to retire and will remain with the Company as a consultant to ensure a smooth transition of the CFO role to Mr. Gomez.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;I am very thankful to David for having decided to come out of retirement for two years in the spring of 2020 to help us get Moderna ready for commercialization in record time. Moderna was an early-stage </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">development, U.S. focused company when David joined us. He goes back into retirement after having helped transform Moderna into a global commercial company. He has built a great team and strong financial business processes. It has been a pleasure to work with him, and I wish him and his wife a wonderful time,&#8221; said St&#233;phane Bancel. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arpa Garay will join Moderna as Chief Commercial Officer effective May 31, 2022. She will serve on Moderna's Executive Committee and report to Chief Executive Officer, St&#233;phane Bancel. Ms. Garay joins Moderna from Merck &#38; Co., Inc. (MRK) where she most recently served as Chief Marketing Officer for Merck's Human Health business&#59; she reported to Merck's Chief Executive Officer and was a member of Merck's Executive Committee. Additionally, she was responsible for data &#38; analytics, digital marketing, and precision medicine worldwide. She also served as President of Global Pharmaceuticals, Analytics, and Digital Marketing&#59; SVP &#38; Head of U.S. Vaccines&#59; and General Manager of Merck &#38; Co. in Norway.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;I am very pleased to welcome Arpa to Moderna as our Chief Commercial Officer and to the Executive Committee. Arpa brings extensive experience leading commercial teams at global biopharmaceutical companies in an evolving global healthcare environment. Arpa is an innovative thinker with digital expertise and broad international experience, having lived in many countries. I look forward to partnering with Arpa as we advance our mission of delivering on the promise of mRNA medicines for people around the world.&#34;</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Continued Growth&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Moderna now has approximately 3,200 full time employees, compared to approximately 1,500 employees as of&#160;March 31, 2021.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Moderna Enterprise Solutions Hub in Atlanta&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Moderna announced plans to establish an Enterprise Solutions Hub in Atlanta, Georgia. Moderna's Atlanta office will initially host finance, human resources, procurement, and digital functions.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA Manufacturing Facility in Canada&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Moderna announced plans to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec that will support a long-term strategic partnership with the Government of Canada to enhance pandemic preparedness. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA Facility in Australia&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Moderna announced the finalization of a strategic partnership with the Australian Federal Government to establish a state-of-the-art, domestic mRNA vaccine manufacturing facility in Australia.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA Manufacturing Facility in Kenya&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Moderna announced it has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish Kenya as the location for the Company's mRNA manufacturing facility.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Global Public Health Strategy&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Moderna announced its global public health strategy through four new initiatives aimed at advancing mRNA vaccines for the prevention of infectious diseases, including a new program,&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">mRNA Access,&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that will offer researchers use of Moderna's mRNA technology to explore new vaccines against emerging or neglected infectious disease</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Company Recognition&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Moderna was named one of TIME Magazine&#8217;s most influential companies of 2022.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Key 2022 Investor and Analyst Event Dates</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Science Day&#58; May 17</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">R&#38;D Day&#58; September 8</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">ESG Day&#58; November 10</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Program Highlights by Modality</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Core Modalities</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Prophylactic Vaccines&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Moderna is developing vaccines against viral diseases where there is an unmet medical need, including vaccines against respiratory infections and vaccines against latent viruses.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Vaccines against acute respiratory infections</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Moderna COVID Vaccine (mRNA-1273</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, Spikevax</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID in individuals 18 years of age and older. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Booster Dose of mRNA-1273&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The U.S. FDA approved an amendment to the emergency use authorization (EUA) to allow for a second booster dose of its COVID vaccine (mRNA-1273) at the 50 &#181;g dose level in adults 50 years of age and older who have received an initial booster of any of the authorized or approved COVID vaccines and adults 18 years of age and older with certain kinds of immunocompromise.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Beta-specific bivalent booster (mRNA-1273.211)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> mRNA-1273.211 includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants of concern, including Omicron. A 50 &#181;g booster dose of mRNA-1273.211 demonstrated superiority compared to a 50 &#181;g booster dose of mRNA-1273 against Beta, Delta and Omicron variants of concern one month after administration. Superiority continued six months after administration for Beta and Omicron variants of concern as well. A 50 &#181;g booster dose of mRNA-1273.211 was generally well tolerated with a reactogenicity profile comparable to a booster dose of mRNA-1273 at the 50 &#181;g dose level.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Omicron-specific booster (mRNA-1273.529)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Moderna&#8217;s Omicron-specific booster candidate is being studied to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 as a single booster dose in adults aged 18 years and older in the U.S and the UK. The Phase 2 study of mRNA-1273.529 is ongoing.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Bivalent booster (mRNA-1273.214)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> mRNA-1273.214 is a bivalent candidate that combines Moderna&#8217;s Omicron-specific candidate and mRNA-1273. mRNA-1273.214 is being evaluated in a Phase 2&#47;3 study. The Company expects initial data on mRNA-1273.214 in June to inform selection of its candidate for the Northern Hemisphere fall 2022 booster.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Moderna COVID Vaccine for adolescents and children&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Moderna has received regulatory authorizations for the use of the 100 &#181;g Moderna COVID vaccine primary series for adolescents 12 to 17 years of age in more than 40 countries. The Company has received authorization for a two-dose 50 &#181;g primary series of mRNA-1273 in children ages 6 to 11 in more than 35 countries. Moderna submitted a request for emergency use authorization (EUA) for a 25 &#956;g two-dose primary series of mRNA-1273 in</font><font style="background-color:#f8fdff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">children 6 months to 6 years of age to the U.S. FDA&#59; similar requests are underway with international regulatory authorities. The Company has initiated an EUA&#160;submission with the U.S. FDA for a 50 &#956;g two-dose primary series of mRNA-1273 in children&#160;6-11 years&#160;of&#160;age. For the adolescent age group, Moderna recently&#160;expanded its previous EUA submission for a two-dose 100 &#956;g primary series of mRNA-1273 with&#160;a follow-up of clinical safety and efficacy data at FDA&#8217;s request, which is now under review.&#160;These submissions will be completed in approximately 2 weeks with the submission of the statistical packages.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Lato',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Lato',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unless otherwise specified, Moderna owns commercial worldwide rights to each of the programs described here.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BARDA, part of ASPR within the&#160;U.S.&#160;HHS is supporting the continued research and development of the Company&#8217;s COVID vaccine development efforts with federal funding under contract no. 75A50120C00034 BARDA is reimbursing&#160;Moderna&#160;for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The&#160;U.S.&#160;government has agreed to purchase supply of mRNA-1273 under&#160;U.S. Department of Defense&#160;contract no. W911QY-20-C-0100.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Next-generation vaccine against COVID (mRNA-1283)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In a Phase 1 study of mRNA-1283, preliminary results indicate that when administered as primary series at lower doses levels (10 &#181;g, 30 &#181;g), mRNA-1283 elicits a robust anti-SARS-CoV-2 neutralizing antibody response comparable to the 100 &#181;g mRNA-1273 primary series. The frequency of local and systemic solicited adverse reactions of the mRNA-1283 primary series administered at lower dose levels (10 &#181;g, 30 &#181;g) was overall comparable to mRNA-1273. Enrollment is complete in a Phase 2 study evaluating booster doses of mRNA-1283, mRNA-1283.211, and mRNA-1283.529. mRNA-1283 is a next-generation vaccine candidate against COVID that encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD). The encoded mRNA-1283 antigen is shorter than mRNA-1273 and is being developed as a potential refrigerator-stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Seasonal influenza vaccine (mRNA-1010)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;In a positive interim analysis of a Phase 2 study of mRNA-1010, no significant safety concerns were identified, and the immunogenicity data was consistent with a potential for superiority to standard dose vaccine for influenza A strains, which drive the majority of disease in adults. The interim data is consistent with potential for non-inferiority to standard dose vaccine in influenza B strains (primarily a concern in pediatrics). Moderna expects to begin its Phase 3 safety and immunogenicity trial in the Southern Hemisphere in the second quarter of 2022 to support potential accelerated approval. Moderna is preparing for a Phase 3 efficacy study in Fall 2022 if needed. mRNA-1010 encodes for hemagglutinin (HA) glycoproteins of four flu strains and targets lineages recommended by the World Health Organization (WHO) for the prevention of influenza, including seasonal influenza A H1N1, H3N2 and influenza B Yamagata and Victoria.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Seasonal Influenza vaccines with expanded coverage (mRNA-1011 and mRNA-1012) and broader immunologic coverage</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(mRNA-1020 and mRNA-1030)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moderna is developing vaccine candidates that may expand coverage against seasonal influenza strains. mRNA-1011 will have one additional hemagglutinin (HA) antigen and mRNA-1012 will have two additional HA antigens. Moderna is also developing two next-generation flu candidates that incorporate neuraminidase antigens to potentially improve immunity by increasing immunologic breadth targeting more conserved antigens (mRNA-1020, mRNA-1030). Moderna started its Phase 1&#47;2 study of mRNA-1020 and mRNA-1030 in April 2022.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">COVID and flu combination vaccine (mRNA-1073)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">mRNA-1073 encodes for the COVID spike protein and the influenza HA glycoproteins. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Respiratory syncytial virus (RSV) vaccine (mRNA-1345)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The pivotal Phase 3 study of RSV in older adults (ages older than 60 years) is ongoing. This is a global study conducted in locations influenced by the epidemiology of RSV and the Company expects to enroll approximately 34,000 participants. The FDA has granted Fast Track designation for mRNA-1345 in adults older than 60 years of age. RSV is one of the leading causes of severe respiratory illness in young children and older adults (65+). The Phase 1 study of mRNA-1345 to evaluate the tolerability and reactogenicity of mRNA-1345 in younger adults, women of child-bearing potential, older adults and seropositive toddlers is ongoing. All cohorts are fully enrolled except the RSV seropositive children cohort, which is ongoing.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Combination respiratory vaccine (mRNA-1230)&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">mRNA-1230 is a combination respiratory vaccine candidate against SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV). This vaccine targets three of the most significant viruses causing respiratory disease in older adults and is envisioned as an annual booster targeting SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV).</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Endemic coronavirus vaccine (mRNA-1287)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> mRNA-1287 is a vaccine candidate against the four endemic human coronaviruses (HCoV-229E, -NL63, -OC43 and -HKU1). While less-well known than other coronaviruses, HCoVs are a significant cause of respiratory disease worldwide. The targeted HCoVs are endemic globally, accounting for approximately 10% to 30% of upper respiratory tract infections in adults.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3) vaccine (mRNA-1653)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 1 study of mRNA-1653 in children 12-59 months of age is fully enrolled. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pediatric RSV and hMPV combination vaccine (mRNA-1365)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">mRNA-1365 encodes for the RSV prefusion F glycoprotein and the hMPV F protein.&#160;</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Vaccines against latent viruses</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cytomegalovirus (CMV) vaccine (mRNA-1647)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 3 pivotal registration study of mRNA-1647, known as CMVictory, is ongoing. The study is evaluating the safety and efficacy of mRNA-1647 against primary CMV infection in women ages 16-40 years. The Company expects to enroll up to 6,900 women of child-bearing age, at approximately 150 sites globally, beginning in the&#160;U.S. Moderna has set a goal of enrolling a diverse group of U.S. participants into the study, including approximately 42% of participants who are Persons of Color. The ClinicalTrials.gov identifier is NCT05085366. To learn more about eligibility, visit </font><font style="background-color:#ffffff;color:#3051f2;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.CMVictory.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In a Phase 2 study, mRNA-1647 was observed to be generally well tolerated and seven-month interim data demonstrates strong immunogenicity in both CMV-seronegative and CMV-positive participants.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Epstein-Barr virus (EBV) vaccine to prevent infectious mononucleosis (mRNA-1189)&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 1 study of mRNA-1189 is ongoing. EBV is spread through bodily fluids (e.g., saliva) and contracted primarily by young children and adolescents. It is a major cause of infectious mononucleosis (IM), and associated risks to other long-term medical conditions, including an increased risk of developing multiple sclerosis, certain lymphoproliferative disorders and cancers, and autoimmune diseases</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">5</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Similar to Moderna&#8217;s CMV vaccine (mRNA-1647), mRNA-1189 contains four mRNAs that encode EBV envelope glycoproteins (gH, gL, gp42, gp220). There is currently no approved vaccine for EBV or IM.&#160;</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Epstein-Barr virus (EBV) vaccine to prevent long-term sequelae (mRNA-1195)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> mRNA-1195 is being developed to prevent longer term sequelae of EBV infection, which are associated with loss of immune control of EBV latent infection, creating longer-term complications. mRNA-1195 is in pre-clinical development and encodes for additional antigens compared to mRNA-1189. The Company expects to test the vaccine in patients with multiple sclerosis, and in transplant patients to prevent post-transplant lymphoproliferative disorder (PTLD). </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">HIV vaccine (mRNA-1644 &#38; mRNA-1574)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The ongoing Phase 1 study of mRNA-1644 is the first study in a series of planned iterative clinical trials with the primary aim to validate a novel vaccination approach i.e., to elicit specific broadly neutralizing antibodies against HIV using an antigen guided antibody germline targeting. mRNA-1644, a collaboration with the&#160;International AIDS Vaccine Initiative&#160;(IAVI) and the&#160;Bill &#38; Melinda Gates Foundation. A second study, mRNA-1574, is being evaluated in collaboration with IAVI, SCRIPPS and the&#160;National Institutes of Health (NIH) to test and compare multiple native-like HIV env trimer antigens. This Phase 1 study of mRNA-1574 is ongoing. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Herpes simplex virus (HSV) therapeutic vaccine (mRNA-1608)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> mRNA-1608 is a vaccine candidate against recurrent genital herpes. In the U.S., approximately 18.6 million adults aged 18 to 49 years are living with HSV-2. Moderna is developing mRNA-1608 to reduce the burden of recurrent genital lesions caused by HSV. Preclinical studies are underway for mRNA-1608.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Varicella-zoster virus (VZV) vaccine (mRNA-1468)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> mRNA-1468 is designed to express varicella-zoster virus (VZV) glycoprotein E (gE) to reduce the rate of herpes zoster (shingles). Herpes zoster occurs in one of three adults in their lifetime and incidence dramatically increases at approximately 50 years of age. Declining immunity in older adults decreases cell-mediated immunity against VZV, allowing reactivation of the virus from latently infected neurons, causing painful and itchy lesions. Serious herpes zoster </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saade A et al, Infect Dis Now (2021), https&#58;&#47;&#47;doi.org&#47;10.1016&#47;j.idnow.2021.07.005</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jacobs M et al, Mult Scler. (2020), https&#58;&#47;&#47;doi.org&#47;10.1177&#47;1352458520907901</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">complications include postherpetic neuralgia (10-13% of herpes zoster cases), bacterial coinfections, and cranial and peripheral palsies&#59; 1-4% of herpes zoster cases are hospitalized for complications. Preclinical studies are underway for mRNA-1468.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Public health vaccines</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Zika virus vaccine (mRNA-1893)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;The Phase 2 study of mRNA-1893 is ongoing in the U.S. and Puerto Rico. mRNA-1893 is being developed in collaboration with BARDA.&#160; </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Nipah virus (NiV) vaccine (mRNA-1215)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;The U.S. FDA has completed its review of the IND application of mRNA-1215 allowing it to proceed to clinic. NiV is a zoonotic virus transmitted to humans from animals, contaminated food, or through direct human-to-human transmission and causes a range of illnesses including fatal encephalitis. Severe respiratory and neurologic complications of NiV have no treatment other than intensive supportive care. NiV has been identified as the cause of isolated outbreaks in&#160;India,&#160;Bangladesh,&#160;Malaysia, and&#160;Singapore&#160;since 2000 and is included on the&#160;WHO&#160;R&#38;D Blueprint list of epidemic threats needing urgent R&#38;D action. mRNA-1215 was co-developed by&#160;Moderna&#160;and the NIH&#8217;s&#160;Vaccine Research Center&#160;(VRC).</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Systemic Secreted &#38; Cell Surface Therapeutics&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#160;In this modality, mRNA is delivered systemically to create proteins that are either secreted or expressed on the cell surface.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">IL-2 (mRNA-6231)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160; mRNA-6231 is an mRNA encoding for a long-acting tolerizing IL-2. This autoimmune development candidate is designed to preferentially activate and expand the regulatory T cell population. The Phase 1 study of mRNA-6231 in healthy adult participants (between 18 and 50 years of age) is ongoing.&#160; </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">PD-L1 (mRNA-6981)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;mRNA-6981 is an mRNA encoding for PD-L1. This autoimmune development candidate is designed to augment cell surface expression of PD-L1 on myeloid cells to provide co-inhibitory signals to self-reactive lymphocytes.&#160; </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Relaxin (mRNA-0184)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;mRNA-0184 encodes for the relaxin protein, which has been engineered to increase expression and prolong half-life.&#160;Moderna&#160;is planning for a Phase 1 study in participants with chronic heart failure. The Company expects that mRNA-0184 will be administered after heart failure decompensation to bridge patients through the vulnerable period.&#160;</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Cancer Vaccines&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">These programs focus on stimulating a patient&#8217;s immune system with antigens derived from tumor-specific mutations to enable the immune system to elicit a more effective anti-tumor response.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Personalized cancer vaccine (PCV) (mRNA-4157)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The randomized, placebo-controlled Phase 2 study investigating a 1 mg dose of mRNA-4157 in combination with Merck&#8217;s pembrolizumab (KEYTRUDA&#174;), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled (n&#61;150). The Company expects the Phase 2 data readout to occur in the fourth quarter of 2022. The primary endpoint of the Phase 2 study is 12 month-recurrence-free survival. The Phase 1 study is ongoing.&#160;Moderna&#160;shares worldwide commercial rights to mRNA-4157 with Merck.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Mutant KRAS vaccine (mRNA-5671 or V941)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moderna has regained all rights to mutant KRAS vaccine (mRNA-5671) from Merck and Moderna is evaluating next steps for the program.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 1 open-label, multi-center study to evaluate the safety and tolerability of mRNA-5671 both as a monotherapy and in combination with pembrolizumab, led by Merck, is ongoing.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Checkpoint cancer vaccine (mRNA-4359)</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; Moderna recently announced a new checkpoint cancer vaccine (mRNA-4359) that expresses Indoleamine&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2,3</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1) antigens. Moderna designed mRNA-4359 with the goal of stimulating effector T-cells that target and kill suppressive immune and tumor cells that express these checkpoints. Moderna is planning to </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">explore initial indications for advanced or metastatic cutaneous melanoma and non-small cell lung carcinoma (NSCLC).</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Intratumoral Immuno-Oncology</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">These programs aim to drive anti-cancer T cell responses by injecting mRNA therapies directly into tumors.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">OX40L&#47;IL-23&#47;IL-36&#947; (Triplet) (mRNA-2752)&#58;&#160; </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dose escalation for</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Phase 1 trial evaluating mRNA-2752 as a single agent and in combination with durvalumab in patients with advanced solid tumor malignancies and lymphoma is fully enrolled. Enrollment in additional expansion cohorts in combination with durvalumab is ongoing.&#160; </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">IL-12 (MEDI1191)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 1 open-label, multi-center study of intratumoral injections of MEDI1191 alone and in combination with durvalumab in patients with advanced solid tumors, led by AstraZeneca, is ongoing. MEDI1191 is an mRNA encoding for IL-12, a potent immunomodulatory cytokine. Moderna&#160;shares worldwide commercial rights to MEDI1191 with AstraZeneca.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Publication of Note&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> AstraZeneca presented Phase 1 data at the American Association for Cancer Research (AACR) in April 2022. MEDI1191 combined with durvalumab was safe and the combination showed preliminary evidence of clinical benefit, with 29% of patients exhibiting partial responses (PRs) or stable disease (SD) &#8805;12 weeks as best overall response.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Localized Regenerative Therapeutics&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Localized production of proteins has the potential to be used as a regenerative medicine for damaged tissues.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">VEGF-A (AZD8601)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Phase 2 study of AZD8601 met the primary endpoint of safety and tolerability of AZD8601. In the study of 11 patients, seven were treated with AZD8601 VEGF-A mRNA and four received placebo injections. Numerical trends were observed in endpoints in the heart failure efficacy domains compared with placebo, including increase in left ventricular ejection fraction (LVEF) and patient reported outcomes. In addition, all seven patients treated with AZD8601 had NT-proBNP levels below heart failure (HF) limit at 6 months follow-up compared to one of four patients treated with placebo. These results support further investigation of AZD8601 for efficacy and safety in future studies.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Systemic Intracellular Therapeutics&#58;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">These programs aim to deliver mRNA into cells within target organs as a therapeutic approach for diseases caused by a missing or defective protein.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Propionic acidemia (PA) (mRNA-3927)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The&#160;Phase 1&#47;2&#160;Paramount&#160;study&#160;of mRNA-3927 is ongoing and the first cohort is fully enrolled. Moderna is enrolling patients into additional cohorts. All five patients eligible for the Open&#160;Label Extension (OLE) study have elected to participate.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Methylmalonic acidemia (MMA) (mRNA-3705)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The first cohort of the&#160;Phase 1&#47;2 Landmark study&#160;of mRNA-3705 is fully enrolled. The study is now open in the UK, Canada and the U.S. Moderna is enrolling patients into additional cohorts. The one patient eligible to participate in the OLE study has elected to participate.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Glycogen storage disease type 1a (GSD1a) (mRNA-3745)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The&#160;U.S.&#160;FDA has granted mRNA-3745 Orphan Drug Designation and completed its review of the IND application allowing it to proceed to clinic. Individuals with GSD1a have a deficiency in glucose-6-phosphatase resulting in pathological blood glucose imbalance.&#160;mRNA-3745 is an IV-administered mRNA encoding human G6Pase enzyme, designed to restore the deficient or defective intracellular enzyme activity in patients with GSD1a.&#160; </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Phenylketonuria (PKU) (mRNA-3283)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Individuals with PKU have a deficiency in phenylalanine hydroxylase (PAH) resulting in a reduced or complete inability to metabolize the essential amino acid phenylalanine into tyrosine. mRNA-3283 encodes human PAH to restore the deficient or defective intracellular enzyme activity in patients with PKU. mRNA-3283 is in preclinical development. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Crigler-Najjar syndrome type 1 (CN-1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(mRNA-3351)&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;mRNA-3351 encodes for the human UGT1A1 and is designed to restore the missing or dysfunctional proteins that causes Crigler-Najjar Syndrome Type 1. mRNA-3351 has been granted Rare Pediatric Disease designation by the&#160;U.S.&#160;FDA.&#160;Moderna&#160;will provide investigational mRNA-3351 to the nonprofit&#160;Institute for Life Changing Medicines&#160;(ILCM) free of charge. ILCM will be responsible for the clinical development of mRNA-3351 and plans to initiate clinical studies of mRNA-3351.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inhaled Pulmonary Therapeutics</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cystic Fibrosis (CF)&#58;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In collaboration with Vertex Pharmaceuticals, this mRNA therapeutic program is designed to treat the underlying cause of CF by enabling cells in the lungs to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) protein for the treatment of the approximately 5,000 patients who do not produce any CFTR protein. IND-enabling studies are underway, and Vertex expects to submit an IND for this program in 2022. </font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information about each development candidate in Moderna&#8217;s pipeline can be found at investors.modernatx.com.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Call and Webcast Information</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moderna will host a live conference call and webcast at 8&#58;00 a.m. ET on Wednesday, May 4, 2022. To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 2083116. A webcast of the call will also be available under &#8220;Events and Presentations&#8221; in the Investors section of the&#160;Moderna&#160;website at</font><font style="color:#0e32e1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#0e32e1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">investors.modernatx.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The archived webcast will be available on Moderna&#8217;s website approximately two hours after the conference call and will be available for one year following the call.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Moderna</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In over 10 years since its inception,&#160;Moderna&#160;has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale.&#160;Moderna&#160;maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna&#8217;s capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID pandemic.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moderna&#8217;s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.&#160;Moderna&#160;has been named a top biopharmaceutical employer by&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Science</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;for the past seven years. To learn more, visit&#160;</font><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.modernatx.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">10</font></div></div></div><div id="ie4ff1c7a0da344909bd16d96b290b608_10"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="padding-right:-4.5pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions, except per share data)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,066&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,229&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.09&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.05&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.58&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of earnings per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">11</font></div></div></div><div id="ie4ff1c7a0da344909bd16d96b290b608_192"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions, except per share data)</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,048&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,350&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,071&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, non-current</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,171&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,843&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,341&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,609&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,669&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,238&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,128&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,534&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,524&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,644&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,211&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,615&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,958&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,075&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,145&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,609&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,669&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">12</font></div></div></div><div id="ie4ff1c7a0da344909bd16d96b290b608_248"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, in millions)</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization&#47;accretion of investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(805)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,666&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,763&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,572)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in convertible notes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,921)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock through equity plans</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(642)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,800)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,817&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,060&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,453&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and accrued liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained through finance lease modifications and reassessments</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">13</font></div></div></div><div id="ie4ff1c7a0da344909bd16d96b290b608_307"></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding&#58; anticipated sales under advanced purchase agreements in 2022 and the associated dollar amounts to be received, which should not be construed as expected 2022 revenue&#59; Moderna&#8217;s ongoing discussions with countries regarding additional advanced purchase agreements&#59; COVID market dynamics and anticipated timing of sales in 2022&#59; the number of programs Moderna expects to have in Phase 3 studies in the second quarter of 2022&#59; timing of new data on Moderna&#8217;s therapeutics development candidates in rare genetic diseases and oncology&#59; timing of initial data on mRNA-1273.214&#59; timing of submissions to regulators and review periods with respect to Moderna&#8217;s COVID-19 vaccine&#59; the ability of mRNA-1283 to elicit a robust anti-SARS-CoV-2 neutralizing antibody response&#59; Moderna&#8217;s 2022 financial framework&#59; Moderna&#8217;s plans to construct mRNA manufacturing facilities in Kenya, Canada and Australia&#59; Moderna&#8217;s </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">mRNA Access</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> initiative to allow researchers access to Moderna&#8217;s mRNA platform&#59; the potential for superiority of mRNA-1010 to standard dose vaccine for influenza A strains and non-inferiority to standard dose vaccine in influenza B strains&#59; the potential for the Company&#8217;s seasonal flu vaccine candidates to provide broader coverage of protection and to improve immunity against seasonal flu&#59; expected enrollment in Moderna&#8217;s pivotal Phase 3 study of RSV in older adults&#59; Moderna&#8217;s plans to pursue longer-term potential indications for mRNA-1195&#59; Moderna&#8217;s expectations regarding the administration of mRNA-0184&#59; and timing of the Phase 2 data readout for mRNA-4157. In some cases, forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna&#8217;s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in Moderna&#8217;s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC&#8217;s website at </font><font style="color:#0e32e1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna&#8217;s current expectations and speak only as of the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Moderna Contacts</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Colleen Hussey</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Senior Director, Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">617-335-1374</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Colleen.Hussey&#64;modernatx.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Investors&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lavina Talukdar</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Senior Vice President &#38; Head of Investor Relations</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">617-209-5834</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lavina.Talukdar&#64;modernatx.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mrna-20220504.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:57c80b23-146b-4666-8a25-01ef75ff6d5d,g:c81cb976-5c8b-46ea-bc1a-80182ef42bf5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrna="http://www.modernatx.com/20220504" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.modernatx.com/20220504">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20220504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20220504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.modernatx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mrna-20220504_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:57c80b23-146b-4666-8a25-01ef75ff6d5d,g:c81cb976-5c8b-46ea-bc1a-80182ef42bf5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_dd185274-80ff-4f75-be04-ed2e0b6c52bf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_331796e2-4755-4e77-a01a-c632a55bf798_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ffe18c77-7164-4e9b-bc07-0ce1bf9c118f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_22c0c14b-71fb-4267-a84d-b50f52a6a4b6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_313ab385-4b57-41d2-92d8-9b53cf1fc46b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0fb828af-dff8-410b-bb7d-129bac51a4df_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d94f6f57-2802-4114-a888-5a50078dffc1_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_bcab2ffa-823b-4425-b152-754fbaaf7e08_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_57125528-982b-4a53-8f19-f8c7152709a8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_592fd2ff-8808-4def-b841-bda0a2f7f2c1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c0f57892-388e-42d9-aab3-164113c0054d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_dfaf2718-f011-41d0-b735-bbe8eb22ab2b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1bacc524-dd65-46cb-85ea-c61430010c28_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_881cd70c-e406-4362-ac47-273603f7390f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a196daea-2066-4ac2-9975-8157d0adaabd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d974d821-28bf-4f94-b8a2-07b2d57b5e9e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2b62720c-d79c-4687-946c-be36c0f2f372_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_75782d34-061b-4ec0-bdd5-c2a60891bfe1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d645a971-0a89-4676-b8db-858ab063872b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_60d2b54e-cb85-4aff-bbd5-26c1015aabab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_466ebaa2-2634-465d-bad8-3d2a23b9a097_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cc15f81e-ee80-4cf8-8b2f-ab44a0c36267_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mrna-20220504_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:57c80b23-146b-4666-8a25-01ef75ff6d5d,g:c81cb976-5c8b-46ea-bc1a-80182ef42bf5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/Cover" xlink:type="simple" xlink:href="mrna-20220504.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f963b88f-caa6-4a28-b74b-5327dec79a52" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_DocumentType_f963b88f-caa6-4a28-b74b-5327dec79a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9c31f350-1939-472d-9b2b-b4f536b04e68" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_DocumentPeriodEndDate_9c31f350-1939-472d-9b2b-b4f536b04e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5453b51b-aaec-440a-89e3-8a51cbd0037c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityRegistrantName_5453b51b-aaec-440a-89e3-8a51cbd0037c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c59badcd-bdcc-4ee2-a261-30a288db05bb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c59badcd-bdcc-4ee2-a261-30a288db05bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1478672a-6bf7-4646-822f-0b0e448801fa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityFileNumber_1478672a-6bf7-4646-822f-0b0e448801fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_43b91ad8-0c87-4702-8e73-a6bd357e947f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityTaxIdentificationNumber_43b91ad8-0c87-4702-8e73-a6bd357e947f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_eeb5223b-ea20-4db6-8462-f98c26d4c521" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityAddressAddressLine1_eeb5223b-ea20-4db6-8462-f98c26d4c521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a95501fc-bb69-4a49-be58-e3f74d9b02aa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityAddressCityOrTown_a95501fc-bb69-4a49-be58-e3f74d9b02aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_aeecc619-84c5-483b-a38d-a85aee760b88" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityAddressStateOrProvince_aeecc619-84c5-483b-a38d-a85aee760b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a53773d9-b590-43d5-843a-24d112e1655d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityAddressPostalZipCode_a53773d9-b590-43d5-843a-24d112e1655d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9f4c945f-b069-44ed-bbcb-70bedb529aa1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_CityAreaCode_9f4c945f-b069-44ed-bbcb-70bedb529aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9a368f1a-9acc-47df-b492-e7b7791adb50" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_LocalPhoneNumber_9a368f1a-9acc-47df-b492-e7b7791adb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_07c56ecb-d405-45f8-843a-c00cfa997b37" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_WrittenCommunications_07c56ecb-d405-45f8-843a-c00cfa997b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3182dea6-5f71-4099-abc8-e9f812384cbe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_SolicitingMaterial_3182dea6-5f71-4099-abc8-e9f812384cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1118213e-017b-4240-86c7-8be033c9d688" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_PreCommencementTenderOffer_1118213e-017b-4240-86c7-8be033c9d688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_10cd34b0-f59f-4365-a003-b3ad7aa9e8a9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_10cd34b0-f59f-4365-a003-b3ad7aa9e8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e3e54602-3ac7-49a9-ab6e-26e6fd310981" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_Security12bTitle_e3e54602-3ac7-49a9-ab6e-26e6fd310981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_850e79bf-9d79-4341-b02f-dce0ef6e33e2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_TradingSymbol_850e79bf-9d79-4341-b02f-dce0ef6e33e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_27212886-58ad-482f-a27d-dc899ab99955" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_SecurityExchangeName_27212886-58ad-482f-a27d-dc899ab99955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_396a5ed1-e933-430b-966f-ecbbd83be803" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityEmergingGrowthCompany_396a5ed1-e933-430b-966f-ecbbd83be803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_77f2ea38-3564-471c-9a54-5aa0bc27ab13" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_EntityCentralIndexKey_77f2ea38-3564-471c-9a54-5aa0bc27ab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a099d656-7a39-4c1f-bfd2-a3823b8d0c80" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1d61bb93-475d-40b4-b9ab-4d4c7a159d99" xlink:to="loc_dei_AmendmentFlag_a099d656-7a39-4c1f-bfd2-a3823b8d0c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140623786629880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODERNA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3467528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Technology Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">714-6500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRNA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>mrna-20220504_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mrna-20220504.xsd" xlink:type="simple"/>
    <context id="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF80L2ZyYWc6ZmY1OTUxOTFmMzgxNGQ4YjljMmZkZmNkYzMyY2U1MzUvdGFibGU6MTA3OTFjNjk4OTdiNGI5ZGI0MjYyNWI3ZTg1NzRjMWIvdGFibGVyYW5nZToxMDc5MWM2OTg5N2I0YjlkYjQyNjI1YjdlODU3NGMxYl8xLTEtMS0xLTEyMjg1Mw_c46e6ba8-77be-44f1-bb6b-1fc4995043c8">0001682852</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF80L2ZyYWc6ZmY1OTUxOTFmMzgxNGQ4YjljMmZkZmNkYzMyY2U1MzUvdGFibGU6MTA3OTFjNjk4OTdiNGI5ZGI0MjYyNWI3ZTg1NzRjMWIvdGFibGVyYW5nZToxMDc5MWM2OTg5N2I0YjlkYjQyNjI1YjdlODU3NGMxYl8yLTEtMS0xLTEyMjg1Mw_83499b90-f321-4570-a2c8-7e9a6fabc881">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NzIyOWVkMmQ3NTNmNDY3MmI4MDc1ZDkzYTdkZDE1YTUvdGFibGVyYW5nZTo3MjI5ZWQyZDc1M2Y0NjcyYjgwNzVkOTNhN2RkMTVhNV8wLTAtMS0xLTEyMjg1My90ZXh0cmVnaW9uOjlkMjYwNTAzMjk2NTRiN2ZiNzdhNzE5ZDYyYTQ1YzQyXzk_1077efb2-e8d7-4958-9064-b60876f1a62d">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18yMjU_65f4f0b5-7caa-4499-846a-9c3e37d9fe01">2022-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18xMjI5_467ecf59-545f-4300-828e-dfa8894ead5e">MODERNA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NTEyODg1YTk0Y2E1NDNhZjkyZTIxYmE5MGEyZjFjODQvdGFibGVyYW5nZTo1MTI4ODVhOTRjYTU0M2FmOTJlMjFiYTkwYTJmMWM4NF8wLTAtMS0xLTEyMjg1Mw_11008b18-cc38-411b-8a08-cfb8fc5adff7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NTEyODg1YTk0Y2E1NDNhZjkyZTIxYmE5MGEyZjFjODQvdGFibGVyYW5nZTo1MTI4ODVhOTRjYTU0M2FmOTJlMjFiYTkwYTJmMWM4NF8wLTItMS0xLTEyMjg1Mw_0dbe28cd-b1bb-4840-8875-76df0b8418b8">001-38753</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NTEyODg1YTk0Y2E1NDNhZjkyZTIxYmE5MGEyZjFjODQvdGFibGVyYW5nZTo1MTI4ODVhOTRjYTU0M2FmOTJlMjFiYTkwYTJmMWM4NF8wLTQtMS0xLTEyMjg1Mw_990b5255-ceee-4cb1-ad4a-7fafe0ddccdb">81-3467528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OWIwM2I3Y2MwYTcxNGU3OWJjNTU3MTdjZDU5OTA4ZGQvdGFibGVyYW5nZTo5YjAzYjdjYzBhNzE0ZTc5YmM1NTcxN2NkNTk5MDhkZF8wLTAtMS0xLTEyMjg1Mw_fb5cd75b-59fb-411a-a547-dcb6994fc4d6">200 Technology Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OWIwM2I3Y2MwYTcxNGU3OWJjNTU3MTdjZDU5OTA4ZGQvdGFibGVyYW5nZTo5YjAzYjdjYzBhNzE0ZTc5YmM1NTcxN2NkNTk5MDhkZF8xLTAtMS0xLTEyMjg1My90ZXh0cmVnaW9uOjgzOWY3MTAzNGI2NDQ0ZWJiYjkxZmM1NjNlMTk1Y2JiXzQ_21f2cd22-5290-4537-aa85-cf3eba9c9a40">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OWIwM2I3Y2MwYTcxNGU3OWJjNTU3MTdjZDU5OTA4ZGQvdGFibGVyYW5nZTo5YjAzYjdjYzBhNzE0ZTc5YmM1NTcxN2NkNTk5MDhkZF8xLTAtMS0xLTEyMjg1My90ZXh0cmVnaW9uOjgzOWY3MTAzNGI2NDQ0ZWJiYjkxZmM1NjNlMTk1Y2JiXzg_9faa7cfe-ae46-49dd-82b8-3b83b4b371d0">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OWIwM2I3Y2MwYTcxNGU3OWJjNTU3MTdjZDU5OTA4ZGQvdGFibGVyYW5nZTo5YjAzYjdjYzBhNzE0ZTc5YmM1NTcxN2NkNTk5MDhkZF8xLTItMS0xLTEyMjg1Mw_ab8fbe07-b014-4e54-ac94-529ec9f66d77">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18xMjMx_48e1d516-acd3-4349-8663-977f1d4e5f36">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18xMjMy_7aa10523-56e5-4471-a585-420aeff0aa2b">714-6500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6ODcxODQwZjIwYTkyNGZiNjhhMTdjZjRlNDI5MjgyMmIvdGFibGVyYW5nZTo4NzE4NDBmMjBhOTI0ZmI2OGExN2NmNGU0MjkyODIyYl8wLTAtMS0xLTEyMjg1Mw_3e0d64bb-0afb-488e-840b-983bff624edd">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6OGIzMGFlMjRmMDBmNGJmZmFjMWNkZTg2NzUxM2E5MzgvdGFibGVyYW5nZTo4YjMwYWUyNGYwMGY0YmZmYWMxY2RlODY3NTEzYTkzOF8wLTAtMS0xLTEyMjg1Mw_4609ea94-b4f4-4115-b9f6-dbfa5db5b089">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6MTU3NjkwZThiNGEzNDg1YzhmYzZhN2UwNWI4NjlkMDAvdGFibGVyYW5nZToxNTc2OTBlOGI0YTM0ODVjOGZjNmE3ZTA1Yjg2OWQwMF8wLTAtMS0xLTEyMjg1Mw_eb75bb3a-510b-462e-8cc7-40d5003dbf04">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6ZTY1MGM1ZTY3ZjkyNDhlOTk0YmUzMDkwMjI0YjIxZDMvdGFibGVyYW5nZTplNjUwYzVlNjdmOTI0OGU5OTRiZTMwOTAyMjRiMjFkM18wLTAtMS0xLTEyMjg1Mw_915bdefb-0564-42a4-b76b-22680d7161ce">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NDQxYThlOTU4YjcyNDljMzgxM2MwY2FhOGI2ZjJhZWYvdGFibGVyYW5nZTo0NDFhOGU5NThiNzI0OWMzODEzYzBjYWE4YjZmMmFlZl8xLTAtMS0xLTEyMjg1Mw_323b09ad-e769-47d0-aaa4-525a29265875">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NDQxYThlOTU4YjcyNDljMzgxM2MwY2FhOGI2ZjJhZWYvdGFibGVyYW5nZTo0NDFhOGU5NThiNzI0OWMzODEzYzBjYWE4YjZmMmFlZl8xLTItMS0xLTEyMjg1Mw_c4086018-3488-4cf8-8a95-537ac08bb645">MRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGFibGU6NDQxYThlOTU4YjcyNDljMzgxM2MwY2FhOGI2ZjJhZWYvdGFibGVyYW5nZTo0NDFhOGU5NThiNzI0OWMzODEzYzBjYWE4YjZmMmFlZl8xLTQtMS0xLTEyMjg1Mw_fe3d0b5e-2505-4dc5-b7f9-fe66965b0cdd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xL2ZyYWc6YmRmMzY0NzdjZGFlNDE4ZmJhNWJjMmExYjZhNjMzMzMvdGV4dHJlZ2lvbjpiZGYzNjQ3N2NkYWU0MThmYmE1YmMyYTFiNmE2MzMzM18xMjMz_d463228a-3fee-4d0c-9701-e346968ec747">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xMC9mcmFnOmM4NjdjYzljY2JlYTRjZjViMWNiODg0ZDBiYjllZjMzL3RleHRyZWdpb246Yzg2N2NjOWNjYmVhNGNmNWIxY2I4ODRkMGJiOWVmMzNfNjY_65f4f0b5-7caa-4499-846a-9c3e37d9fe01">2022-05-04</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzNDIzMTg2Zjc0NzQzYzNiMGJjMDA5MmU2ZjM1ODg4L3NlYzoxMzQyMzE4NmY3NDc0M2MzYjBiYzAwOTJlNmYzNTg4OF8xMC9mcmFnOmM4NjdjYzljY2JlYTRjZjViMWNiODg0ZDBiYjllZjMzL3RhYmxlOjljMjBmNmRhNTdiOTRiOThiNjg2YTA2ZTc5OGZlNGViL3RhYmxlcmFuZ2U6OWMyMGY2ZGE1N2I5NGI5OGI2ODZhMDZlNzk4ZmU0ZWJfMi0wLTEtMS0xMjI4NTMvdGV4dHJlZ2lvbjo2YmYyMjNmZDY2OTg0YzMyYjQwYzVkZDc2MWY5OWFiN18xMA_65f4f0b5-7caa-4499-846a-9c3e37d9fe01">2022-05-04</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $HWI%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !*-Z14DT5QG^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.LT80E'7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y
ML^0:@\8^TG/L T5VE*Y&WW9)8]B( W/0  D/Y$TJ<Z++S5T?O>'\C'L(!C_,
MGD!)>0.>V%C#!B9@$1:B:&J+&B,9[N,);W'!A\_8SC"+0"UYZCA!558@FFEB
M.(YM#1? !&.*/GT7R"[$N?HG=NZ ."7'Y);4, SEL)IS>8<*WIX>7^9U"]<E
M-AU2_I6<YF.@C3A/?EW=W6\?1*.D4H5<%_)Z6TF]OM6J>I]<?_A=A'UOW<[]
M8^.S8%/#K[MHO@!02P,$%     @ 2C>D5)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( $HWI%0'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ 2C>D5)-%<9_O    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ 2C>D5)E<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !*-Z14
M(V[=E2L$   J$   &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ 2C>D5)^@&_"Q @  X@P   T
M     ( !;PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !*-Z14EXJ[',
M   3 @  "P              @ %+#P  7W)E;',O+G)E;'-02P$"% ,4
M" !*-Z14JL0B%C,!   B @  #P              @ $T$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ 2C>D5"0>FZ*M    ^ $  !H
M ( !E!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M2C>D5&60>9(9 0  SP,  !,              ( !>1(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  PQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mrna-20220504.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mrna-20220504.htm">mrna-20220504.htm</File>
    <File>exhibit9912022q1pressrelea.htm</File>
    <File>mrna-20220504.xsd</File>
    <File>mrna-20220504_lab.xml</File>
    <File>mrna-20220504_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrna-20220504.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "mrna-20220504.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrna-20220504_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrna-20220504_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mrna-20220504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mrna",
   "nsuri": "http://www.modernatx.com/20220504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20220504.htm",
      "contextRef": "ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.modernatx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20220504.htm",
      "contextRef": "ib150aa1f9e104014ad7f45d848b3d9fb_D20220504-20220504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.modernatx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001682852-22-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001682852-22-000020-xbrl.zip
M4$L#!!0    ( $HWI%1:)M8W+5H  -9< P >    97AH:6)I=#DY,3(P,C)Q
M,7!R97-S<F5L96$N:'1M[7UI=]M&ENCW]ROPG.ZT=![)$%Q%*YUS9$F.-;%D
MC:0XT_.E3Q$HDHA!@(U%,O/KWUVJL'"12&T$*<SI<2@2RZVJNZ\__]^3+\<W
M_[H\-4;1V#4N?__P^>S8>%?]Z:<_FL<__71R<V)\NCG_;+1J==.X"807.I'C
M>\+]Z:?3BW?&NU$43=[_]-/=W5WMKEGS@^%/-U<_X:-:/[F^'\J:'=GO?OD9
MOX%_I;!_^3\__]]JU3CQK7@LO<BP BDB:1MQZ'A#XP];AM^,:E5==>Q/IH$S
M'$5&H]YH&'_XP3?G5O#OD1.Y\A?]G)]_XK]__HE>\G/?MZ>__&P[MX9C__.=
M(UN#@6EU1=T6S5:K5^_U;;-C]SK]1J_>[]0/_FT"D#_!Y7Q/&$U=^<]W8\>K
MCB2^_WV[-8D.[QP[&KTWZ_6_OZ/K?OEYX'L1O"R F_DC/V/N29'\'E6%ZPR]
M][2>=WRK_MGR73]X_T.=_N\0?ZD.Q-AQI^__<0QW]0/G'Y40]KX:RL 9\ 6A
M\Y=\;YH %OUYQW!VX7[7\:2&VVP@L*??1T[?B8Q>KV;F(5T,HP4[*H-W2]>W
MPEVOM;1SWY:!)XPK.?&#*#0^.D$8&?\=BP!@8;3YZ'C"LQSAPD5A[,)%PK.-
MR\"_=0#=C ^(>C(,C=\G-J!BN'2I8Q$, 2/Z?A3YX_<= &\B;!O0MNK* <!C
MUAKMS)<!0ZF^77-W5\/:IME:A+</G4E?6-^&@1][=E4=SX#^[_ 9#HM>\=Z)
MX'(K=WRMA<?'Q_6?['$%\E9Z,1R,/S#^IG?FF5%J32@[-=/H.ZX+G&\10 7:
MSQ]_:/<.C5^/CBX-3T95Q[/\L2S03C9KW:W92;-3/T1.0;MI.VZ,<NKT\KI
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MQQZ0R0>-1OWP!C9/2X5(BK%A2]>YE0%* H 1>-'0^&_3F,@ MGI,D@%/Y,R
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M;M$?@)=NZ!NN[W]#M+P3 ;V$T5?C3(97IDB'N!".!'%8^-(?5.%_@%66G$0
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M*D$P49<Y><G.)!T(S^B3]PI]7M%]@#;K;7/0>-5<-"Q(&3,A1M]K8$40H]3
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MY14Q$3:[F2.A!.!/GSY=(^=2!8^Z8U[JJM-Y^UQUF^DGKKNVS0P>RNMFV1N
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M/.'3D;XCS'%XZGN<61S>-FM#(!^>72RPR:3Q*2C^@4"=UQ;4J)9?0XXV+6I
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M3.33_1D2H"(F(  F34,]8R\<48-EK-W]E/O%MX!0R$Y(<KPQ&5-1*D=LG,!
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M%9;454CJ^A7;$&*CX##R YQ_J)TC-/_1!#K[]?K$%"FEM0I-:>E$*OZDNS^
M9D;^KV01QI=@@LT*3H)X:)Q07H[JQZR:_J[:*^+A]A#8L>#6L>.D133M*(L<
MS D"E1ZHR2)-?NC&EA_*:J<ZP8Y'(Q&)Q%90[5: :D;<FP&]8J[OV_HNPQGW
MA8M.NUJFLHI6RQ[LLZ_57,%1WJ/-S25^[5Q2#97WUW0L*[F"0@ CPAP,W 8-
M=I37/YV<ULX/X9I=U1<R[YBGG=C6N-*.<8++D?2F[C<9^5X<D,+ZV^\)V3<.
MBMNL:(Z^ /#%U#6A)2*)H%=O-+4#_SO\C:[@RZ-/^WDZ$ZH7*Z44:8X /VC_
M#6:/RTCT,6F8:0*S,MFMB#F9/NDJ,^_D9(XICDO J%"RN4GI(Q,A0/,R! =;
MDWUK,E9BT52)>UJ3E_E_ &?O+>3_E7QT73YZ#*?CRJ!Z(?[\$T@RG'K 9L9:
MH3+VCB^J9M%RU#>HRBUV RJQTVP7O'D#0CA7MLX\_/=?;\PC4W>96J9'9;UX
MTW 0>Y8RNO)]?52'KQG<NM:X=4.XI3D[PI34R&O-]XH'H^I9VB=*S;<SJF]_
MFA_JFJC0BZKZJ()==XG(.:T!^!0.-<S5\SVX=N!$6F2KX1NT9Y^=@32.01L?
MXDZ<JZA;J >)?#X^QT(LR?'@$?I-0:F&;Y,J>A6CS?E]%LY)2HQI!(V""Z[@
MPFC.*XXR]^DNHME[=C,(?.:-!)7;QN[8IPA\UMV^;6KY;B6;'$]## =\A*?S
M\,SCCX6UO\\6=O3\*@,X=(R=!F/05&.J^@DKJN%9FO3,<0\519EEF11)([KF
MH<93AS+V5;O XX_(NZBW 7U/<1;EA,+<?MW1AD8K9'BLQ9L[T)O+C16Q$E#P
M"#=,(D![.FTOA0=P<[6OV7/";G(5X%0;GI^:4($MS^CB(]^P?>"*40(6EGSC
MHY,0#GH:JLF:%O4TYN[*:G\SL]O"N$]!2X^<%0PA5O;HK?54YLYV,+,'4 Z6
M-U:>&)[1C4&S)?V1O+FYEQ-G0F5G>!5*D@&N <.]+-$PYW[,MT3?<6SVE@B
M!]@]+\TXQI YHM ?LF^),#(RN[GB.F=&7;2+@QG:Q4TZPLC'<5XXE8C(FAK*
M67CH:@/NU ; P1\0=\7VH+5QS3B]P<8L?T@;]!$;*>Y<3(U617=60!O?4C5U
M"Y^.;2U8ST*WP$&G4^TU&M4VM@#:LS&) ?@/I::UZKUJK]FM'O3:=6//R0Y:
MXS0(:H-';L7T#6<G ,A!TS0[.#=-+T(Q(%H<K1[8+:4YB5OAN)0!1QS$(!E8
M/SR])9Y$W9LY49#KJNAG\U S4HTV(7:6S(QD6:0;RCX8^/#"Z+X O6PVI/FJ
MYLS+OIEU&VS8Q.+O/8LJ*FI=PDX*)+[O@WY3;0SN2<7"A%3*;])8GW342I#<
MGV?W"6+FA'-TYP.'P-E)W(&+4U07<(FY5Z!LQ8 8]H-4B4%4.JO(KUB9./<*
MA2,2GFJ_B@CV4I43$W4-4_?DY/[.#D4Q+3FAU+ %'(HR05';0X&G&V<):MB#
MF 46%,;"+-6*A^L'*$:JDWQTSQU'NC:9B.3\Q1'"J-&2^V*?IGD*3*8#K)H$
M8'&K<@20!@!TF#$V,04,\,?Q\5EZ<H..V2:F&$B; ,<,<YJ;:A8,6B&6(-"4
M4.J][6*@-687P@24PVGFZ>C7QCR\3&9>DC?H.A/'-CSA^1R?9?P>JR:JK&RJ
M]M[#@/+:P J+!P)>%M#>T#!?;D.,E, .$2QGM-.%JO":KG;().K";5B,MK [
M'R89\O!Q>+*#&KFN[%#K3AJ?:Z%*+_)IES'\AY^\9%1R!H#48*&2D+3!("U!
MS1JAU$[@#[%#TI4ZBS#K(\\NZ><49> 4=UXR+H8\.X/\/F'TG4<P4BN(RAR3
MLL2$8PRH[U,<PR+_H3^4W&3=9^#8S(BCD1]0TC,:0W1&-$"=NPDDD^ D*,;
MS?58TS&"D+9X2S%.#6+#&XZ_? 4% SOL8D)>(7G9O:I?LJ&$X8"=$:*ST8\=
MUZ9^>]AIS/%BK Y7%4)$UWT1*ORA.*^.DZH3KNC$/I ;TAIY5#C->YH]92:7
M+")Q$"?GB\K3MF>GYX!8I\?HQ&&2 %A1)4957U5L5P#9 IGYW1*![<#IAYQ9
MFV0.TG+BR*_J#K+JAT74EO@./3&F#B5PCD;?\2<Y$]Z0XXGK3P$A=?OZ8F1C
M7O,Y;2))G+<AX1BHEC"K)ME$]@)8 X%''18KQJT3:H?H/= VZVUST'A5?>_N
M[NYA/?6E-W.>X2R-=)61R7QDTJPO#TWB$AS[G^\<V1H,3*LKZK9HMEJ]>J]O
MFQV[U^DW>O5^IW[P;[/^KMCQS,QN<SWIBV_W8MWY_,O)*4B(BG%V<;Q<3!8%
MVN,O%R>G%]>G)R#@+ZZ_?#X[.;J!/ZYOX#_GIQ<WU\:7C[B2+^>G*XK\9A[S
M-[JZO=\] 7IMA!U%09:K<=4@&.5W- >P+;)!Y;=4 IG$8;DP,.$&-.N55,-)
M*-_K#X<@-$&-F+YW/'HQW;1@]NM,:RO:&OXYI81:G:DA BR/;/UF]7.-?OHI
MLN=_ZYJUMME;^G.]9C[RMW:K]:@[[P/6-&L'K<XV =M=];& $R&HQO]\UWRG
MK]/8X?DH0XMPY4^$7<&FP=C TI1D>5\W3!ZXO/SI#U[:F[NT,?F.%\\SO;FN
M=D3US\T*#Q[BA'7.AL60^;E/16NG'DZX.J<R[J9921C[#AQ/>JGBVV1U)@.Z
M<9\/M^K@,+:PP@$]O-HWM67FB^/T!NADWL=N65(.!O>=#J8/S)[-V+%M5RY6
MOBG=H#>;FM';1&8&G>456LQQOJ6&,@#NP>.'-FH56ECVC*5$LBZQ;0.0.T C
M*@XU0R,&_;>W!K%L OLOV2%NA,+-C&Y>!Q]F5C][Y.OL6MU8D;^\#.]?<<O^
M-KM-:RUQSF=3J+6U*[U&>V:&SR-6J=%_C=66./=6<<ZL=)O-HN'<#HBEQ:K;
M=HBE7S&+'"LA435[E%A:5=5IK+>#"]E% 6FJT5F3HN[!EI?BXF_\B'JMHAW1
M#C"];=;%CW/)[$]A?@_H1RM1UJJZ4@$I:_LUV%T_H7K13F@'6-\]XJ'9+3CK
MN_$C:J%:"'UO-2?UEI!:IU+O/%(77-E9ORU:XDX=K%GI-;O;<[ [P& 7"Z%=
MBH5\F5 O8AP%]AV'@*LIUT\(BZRJYZSPC.<)0!8>PAT@E&WV/!W[H6JC_-B
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M>_P+1]8:D\"_=5#=[D\S [!3S>!-YWNO)^1[A5'\[DGJK_9%B..*_?%$>J%
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MX0_U+_H$X3^C:.S^\O\!4$L#!!0    ( $HWI%2]+6]+@1<  %6=   1
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M7-F I1F+BDH?8YP.  'L),^3N"8!G>!6Y8&#HV4G17_EXR4V\&Q5Y&0*#SF
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MO-[!-97Z8HC"W\]K>_:P;I<,@HR&X',#GOQ>8C^CYN%W45:(XTD:DD3)0Z+
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M3/0+PV8+Z(*R>@AU 0*-UM>X'Q^&>L\8]H%>8W$ZT_FFI"\&UV#3"O4I>(L
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MW#M#D;W4?DO.S6X:[DO+X8Z[3%]8$;:BZYF(*5JL!3F8O<X]R-N6:7K5,VW
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M7YXJ\BOO>U[\E?Z@ )S4)YWFU_=%>G%9>AAB_/3;XE48<P(9]@$*(@:"*(H
MH3@$$$D5ATI%(A2_7+SB!'&6Q!$(.:G,) 6,(PH(1 1+%6"FPMKI,LW^>E7]
MP^A*>CJX;%7_^69V69;7K^;SV]O;EW>L6+[,BXLYAM"?;ZUG&_.[COVM7UNC
M)$GF];</IJNTSU"[1?,__SC[RB_E%05IMBIIQJL!5NFK5?WA6<YI67.^%Y<W
M:%']!;9FH/H(( Q\]/)N)68G+SQO34>1+^47J;SJ_V]?/@P.F<PKBWDF+ZI?
M]K,LTEQ\+6E1GE$FEQI][:V\OY9O9JOTZGHIMY]=%E+UNUT61<MKA3*I4**H
M0OGWH<'F(^ _$]ZRB_49P-7A?GPNC+LX_?AL<,]U?I"'!]P89C3D]07U+A-3
M7;L/0XV&?GC$SW59Y"5=3G!9/ [3@+RL/CC31YMA*D<[DFD]SB9U-Z#*NU)F
M0JZS9<NUEXHW,WVT$#)=?"[D:7ZEZQZ75?$[K\XI/BDEBX40B(0X#G0I4@H$
MNF@!)F$ I, 2LHB'NC0MRH<K>R$S\.WK%D0]DLDP,XLHRP&U%G*5WQ3\L<Y=
M+?N*EZY;5:4C\XQ>R=4UW9R@L58MP1K^B48*> .JM\;JU6!?SQ^#<^9U.1%;
MRV,D*N<M0,NJ6<B+ISSDW)"'1PFN= @U"2O)7U[D/^;:@28#H^H 5 >U\O:X
MG7=^U;?%%C$M^![:-Q9SGFO7UR5H_0)5#VD36IG;7!!K.C6 F9<7^DO=\?8$
MT[I$WVI7HG+W?DDO%KZ/XB22& 1Q&() QC&@4/>A//(Q#4.FXH28JKWE^=@$
M_@#.J]"9*[I-UWX1.Y-P8-T:QF\EU-Y8G;39]C29''L#:"JPW\!>=.^R,BWO
MWPJA?]*5GA64\E/QN<A_I!KB0@L:$:Z5%Z,HT!I,F)X+PAA +A%3"4>(&%?<
M70,=FR376+T-V%^\&JZFU-L"-E?I3G[WB_:Y6#NPAMT)LY*U"1M.*M_I>#+1
MFX37S %&]JXIX9S>?1 ZOZ0J7:^??+RY8KI;Q)A#C@*F<X)B(,"1KLLD$("%
M4(681C1@D5U.&!CI2)."1NNUX7IKO+8Y88A@TZ3P#+1-DQ7L&7-("GO8&)$5
MACQ/G!;V!-C-"_M.L$\,7R6_*;1GA-EY6B[EPD<^93[1[3D+8Q @@4&"!0$)
M"WVND.)!Q$QSP5/GQR;_&I27*P_A?[!_>ENXYJKOL+=?Z&,X.;"V;>FPDO10
MW$XJ[CB;3+A#832U.FCC6K??ITNYJ210,8()54 H1;0\H6[?62P P@FC/$0T
M$);M^Z/S8Y/GIM94 !WK<8,XTQ+L1L<T5=>$"8<ZVPUY1&EM.)NXFG;#Z!;0
M'AM[47[7XBYE5JV6W62;0KQ:B"10D=(U$Q.(M3)1H)MH0D!(0PACHO7*D:DR
M>T<X-GEN0'IME.82[:=QOTY'DW-@L5KR8B78G;$[J;;?XV32W1E04[^[#>U%
M_&2Y^\-J=2.+YA8*XY1AI2@@V->3X@"'@*$0@S@,%*-4Q1(:+U;O&^S8I-W9
M=UDC?IY]JB[5UKM5HPB<>L_*AKLQ6U>#I#S'!E;7^<_:QAH,<\=FUO YKBWY
MNRM97*39Q>]%?EM>ZK&N:7:_"&.$PQ#KV3+!.F?0T =$H00HPF.=.V*84..<
ML6.<8TL7F_9TB]5;@_4V:&V;]GYJ3?OWT81-T\K;<N70UN]D8D2'W^]WXF9_
M9W#=OG^WN7T2."]H=9/GU_LKEB\788*5T+T"( 3J2;F0"C 2(, $A12K6&'S
MUK_E^=B$O@'GK=&9"[M-UWXI.Y-PZ!4RL_BMQ-H;JY,\VYXF$V1O $T)]AO8
MBVY[]_3#+8._T5(N.-23;I)@X!,B08!% BAE/D"1GH/[',(P$*;BZQWAV$3X
M<!/Y&J6G87H53G,Y]A.Y7Y:CZ3FP/*V9L1+JSNB=!-OO<3+A[@RH*>#=A@Z;
M3ODRY6FI<\(?VE&1TN5"**IPC A0$*%JVPD"%OMZRLTDD0QC/1<WWW;JN#\V
M"3\B]+80+3:=NNP9;#N-XN3 NK6APV[3:3!JMVVGKKOI-IX&0VEM/0U;N=?;
M<WWJ C'*>8@#($04@B#B#)!05O=NHL"'$$&.C:>V3<?')LV'&E*!LR^I-5?F
ME=26@:D*Z,[@G:IF,])1Q;)V-'F-;,+O*XVM[^VE=EK=]%5(>IH+N2 $<1%#
M#F0 (Q#X$0:4!S' L1]!7\5^ HWW>)N.CTUJI_7]A1J<5Z$SUUJ+K/U:<Z7@
MP%HSC-Y*;'VA.HFMY6@RL?7!;XJM]WO7%=P/&<^+Z[RH=Y+J.RU/\YNL+.[K
MRXJB)!)4US<,(ZU!RC%(DC@$!(6Q@%3H*:;QK-)@O&.3YF:5LH6Y<0OP!KFE
M;DUX-UWF?38VIUGN'46DP]JO$3TCUH!W^Y]X+=@HV.Z:L-EI(Q^_V/QWEF82
M+402!X)@!#!AU=..20 8H1C F&$1QBR4B71Z]J(YRI&FDH?G"#8'7@76^Y2Y
M/G?1(M8T:XRD:YI<8<^4^P,7?4R,?]JBY?7G/&K1%]C@<Q:]QJ["_R(OTE59
MT*S\J'_K!681CK%NYD6<<#UO)C%(].P9,.E''"JL_!C;:;X]P)'*_1&D5Z&T
M%?D3$DWU[4[---(V9<5!T/VAC]#R$X<3R[@_G*Z"!^SLQ5N]4F;Y^3+/MC<,
MQV%,L/ # "/$0" Y!$R($'!,(T@2Q)0TWM1]ZOS81%OC\VJ UG=:=XC;+]8Q
M=!Q8J!9,6(ET*&0G@7:<32;.H3":PART&=E*5[/_3\5Y?ILM1!2$-(D1@)0D
MNJC&D6ZD1;4B32B#D4]B\]VB@3&.3:)/F\-Z^4C/("NLCBUT@U#+!MJ-IHG;
M9R.&W%OG+@?C&^>&SY_3-G>#&FR:>TP=UKWS'[)XRZH*SDN3M=RF_1%=>S4N
M[[];9/][IN7<OFC=UG-;GJ9;T.T+H+6BVVLPLE!\SE<E7?XGO:Y7%",H, L#
M"3BKGFJE2@'&=!^'(XX@"BEEU*U6M(8Y]G*Q!NMIM$Z+MKW,6A8-9[XFKANF
M5+F7CEXFQE>/MMN?4T!Z0QNL(?W6KO(_E9G.(\L/F9!W_Y;WBR"*)*,4:ZGK
M:5P0A0(P*@CP!:;89PF%26RG_"<C'*GH-RB]&J:G<=JJ_2F1ID(?0<\T&C=G
MQD'< ]&/T/53CQ-+>B"@KIJ'#-U?1_'NCE_JWT_6JW^<HU 1)(&4!(* *P((
MPPI0%@04<C_"D;&.^P8X-AEO,7I;D)9+J+TD[M?P6&H.+&%+5IQ>3M$7^J@7
M5+0<3OZ2BKYP^EY4T6LW)-XFXV?ZZ.3%]I-T_2KMDQ?_!U!+ P04    " !*
M-Z14>Y%<!*@&  #>,   %0   &UR;F$M,C R,C U,#1?<')E+GAM;-6:6V_<
MMA+'W_,I]FQ?2R_O%R-VX;K)@5&W,1(7*<[+@I?A6HA6,K1R;'_[,Y+M-FLG
MK6 M8.5E+Q*I&?[G)W(XTNN?;M;E[#,TFZ*N#N9LC\YG4,4Z%=7J8/['^5MB
MYS\=OGKU^C^$_/GS^]/9+W6\6D/5SHX;\"VDV7717LP^)MA\FN6F7L\^ULVG
MXK,GY+#O=%Q?WC;%ZJ*=<<KYX[/-OC+1TL %85('(K76Q'JN"&60C<I9)Y5^
M7.U'RV)P1A,5;=<,/ F1>6(ILQRRY"&K_J)E47W:[SZ"W\ ,!U=M^K\'\XNV
MO=Q?+*ZOK_=N0E/NU<UJP2D5BX?6\_OF-T_:7XN^-7/.+?JS?S7=%%]KB)=E
MBS]_._T0+V#M25%M6E_%SL"FV-_T!T_KZ-M>\W_U:_;-%MT_\M",=(<(XT2P
MO9M-FA^^FLWNY&CJ$MY#GG7??[P_V3*YKA,TE6]O]F*]7G0M%L<U\H"^]GW;
MVTLXF&^*]64)#\<N&L@'\S5V(UU0J:*RL_C#7<?%WX8O&]@@*_U 3_' ??_.
MRC.<@)L6J@1W(WLP4=9QJU'9Z5K_U;/T <K^Z#)!L>RO>A0V;>-CNV1)LQ"<
M(-*H1"0-D@3G$:\DH_%,N>3<]I@[GS?H=!^&#<2]5?UY@1?&<'#6_>@$Z>7_
MX8FY.V&>Y_?#77>.;9?9:1&LS21ZKXGTW))@9"!*<),@&N<5'^7VE]:VO?XR
MH$=-G-4-!@ZGC0=SOHE/@KN-['V+Q:5O\$(D7A1E>NC=S1^[B%5;[T"YN["@
MN_,9CCI#TT ZO8O*-P?7CZS%R13ZEKN(^!DT19W>5.D7G&V7+@J6A:*$.>%0
M"IZ("SR0(+,2.E )VNXD]%MF!S' I\_ \[5\81C>5&W1WKZ'5=$I4;6_^S4L
ME50B*!:(]Q")E!170P<"ET^%:V5"%TP<Q<+7K Y"04P7A=%*3H*$$\S0FLNZ
MZ87_@/K#<7U5M<WM,2ZDRZA<\"DF$E+$X0!PXKEF1%"<\&P*5(6P S#^T8E!
MG,BI<[([G2>!S=NBA-^OU@&:)9/&:L,]T2$;S*<EIMV<9T(#!2DMIM79[X"1
MORT. D)-'8AG*CB)Z)_[FY.$6A6YN-MZW ]$BN"83Y;0:'$@AG)BP0CB=4A"
M&7#2Y!V@\ WS@[C04^=B%]I. I*CE# $F_LOW+,!6P($Q;D(!#RG*$A TJ7F
M)#L;N49]%&<[ .0KI@?!8:8.QUA-IP3&,?Y\UYS7U]72.Z5PDHLD!(WYLY>.
M!%"6@,A&)A<H][M80IX8'@2%_4Z@>*:>4T*BSXO>-6=-_;FH(BP]0(R:.00Z
M*B(M0NZ%3<1;A:>,IK@#WQT7CZP/@L-])W",479*A)S5F]:7_RLN^[39*V&,
M2$BW<CCUB:1P/,(3+A-C')A6*NV.CRW;PXI9]#O!X_FROC <W:1WU(#O_799
M1B=5)H%VTYX$W$^%&(BA 1(NDL[[<=G%E]:& 3#A<N:SI7OAD'>/.\JSB[IZ
MV#XY+[3-S!/GN\VS23@*Z3@!$XSI<N:@Z*BP/[8X+/03KF*.DO"%P_^Q*=H6
MJN-ZO;ZJ[K=(FR4U46E 8).DN)ZI;.^FK$AIS-XY$X09Q<!7S0X#8<(US/%B
MOC -'^JRB$5;5*O?,,%I"E\N!;,\@==$9<-0"^>(#Q&37Y<MXP(3G@"C4'AJ
M<Q@'$ZY1CI3QA2$X:Z C&#"Q[9_/=8]VFW<Y=Z4UAL-@ @AE!F7@DA*KHR$V
M !4BNJ1'[B"^;7L8%!.N4^Y(UFG!<;+97$&S-18:DY"!DJQ<QFQ7*^*[UQ^"
M\,EX[\#Z<8_N_\V#8:!,N'"Y4XE?>D&!>(6+XBWCX;QH2UB" "4UY41X!%PZ
MW\V#&@C7H',2C#H[;E/QV.(P'"9<JAPEX0N'_[SQW?MJ'V[7H2Z75E$P+F3B
MDL%=D9 ,]T<\DQ2!0M8@!(Q[/6;+W+# 3[@<^7SQ)G+3O[F)%[Y:0?\HGQO.
MN+68 %F/*EATW7.3T'_K4 WGG%([N?&_M#J,@0E7'4=+.8EJXYLU-"M$^;]-
M?=U>X.)VZ:O;I7#:*T@,<V"!P@@:B-,Z$]PJA61% $O%*"+^P?BP%Z<F7V\<
M+^PD^#A&R1I?GF"*<_,KW"Z-R1R\L$0H+5$9%HGS2A+E/0V1&Q_8+LAX9'88
M$Q,N08X7\X5I.,)\-W4Y[]O2KY8>-\E)*TV,[UX#C"R3D!/OGJQP$6RBT8XK
M1&Z9&Q;]"5<AGR_>SJ+^>O%$O%,\</CJ_D3WT;T0?_CJ_U!+ 0(4 Q0    (
M $HWI%1:)M8W+5H  -9< P >              "  0    !E>&AI8FET.3DQ
M,C R,G$Q<')E<W-R96QE82YH=&U02P$"% ,4    " !*-Z14O2UO2X$7  !5
MG0  $0              @ %I6@  ;7)N82TR,#(R,#4P-"YH=&U02P$"% ,4
M    " !*-Z14EGHF2VL"  !Q!P  $0              @ $9<@  ;7)N82TR
M,#(R,#4P-"YX<V102P$"% ,4    " !*-Z14^>Z1%%,*   870  %0
M        @ &S=   ;7)N82TR,#(R,#4P-%]L86(N>&UL4$L! A0#%     @
M2C>D5'N17 2H!@  WC   !4              ( !.7\  &UR;F$M,C R,C U
@,#1?<')E+GAM;%!+!08     !0 % % !   4A@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
